Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REVO-UWD-01
- Development stage
- Phase 1
- Lead developer
- Wondercel Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
REVO-UWD-01 is an investigational universal allogeneic CAR-T cell therapy designed to target guanylyl cyclase C (GCC), a protein highly expressed in colorectal cancer cells. The therapy uses T cells from healthy donors that are genetically modified with a chimeric antigen receptor (CAR) specific for GCC. This universal platform aims to provide an off-the-shelf CAR-T treatment option, potentially improving accessibility and reducing costs compared to autologous approaches. The primary indication under investigation is metastatic colorectal cancer, particularly in patients with liver metastases. The drug is being developed and trialed by Wondercel Therapeutics (also referenced as Wondercel Biotech or Shenzhen Wandao Cell Technology). Early clinical trials are focused on evaluating safety, dose-limiting toxicities, maximum tolerated dose, immune response, and preliminary efficacy outcomes such as objective response rate and progression-free survival[1][2][6][8][9].
- Other names
- Universal GCC-CAR-T cellAllogeneic CAR-T cells (REVO-UWD-01)
02
Targets
GUCY2C (Guanylate cyclase C receptor)
Beyond the preview
Go deeper on REVO-UWD-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REVO-UWD-01.